Source

The 09-01 crash that the tape read as an unexplained price step was a failed Phase 2b lupus readout: envudeucitinib missed both endpoints in the overall population, with only the prespecified interferon-high subgroup responding. That is a smaller addressable market, not a dead program; the psoriasis filing is unaffected. A biotech that halves on a subgroup-only miss is a story about what the market had priced for lupus, and the bounce on 09-02 (+9%, RSI 20) is the first read on whether anyone believes the subgroup path.

Takeaway

The 09-01 crash that the tape read as an unexplained price step was a failed Phase 2b lupus readout: envudeucitinib missed both endpoints in the overall population, with only the prespecified interferon-high subgroup responding. That is a smaller addressable market, not a dead program; the psoriasis filing is unaffected. A biotech that halves on a subgroup-only miss is a story about what the market had priced for lupus, and the bounce on 09-02 (+9%, RSI 20) is the first read on whether anyone believes the subgroup path.